Novartis Receives European Approval for Eye-Care Drug Jetrea
European approval has been received for a drug named `Jetrea' by the eye care division Alcon of Novartis AG. The drug is used in the treatment of vitreomacular traction (VMT) which causes holes in macula, the area of retina of an eye, which can damaged the central vision and effect the person hugely while driving or reading.
Novartis is of the view that the condition of VMT can affect around 250,000 to 300,000 people in Europe. Area president for Europe, the Middle East and Africa at Alcon Stuart Raetzman said that with the approval of Jetrea, people suffering with VMT need not undergo surgery and the one time injection of this approved drug can treat the patient.
ThromboGenics retained the rights of Jetrea, which was approved by the USA last year. Dr Patrik De Haes, CEO of ThromboGenics, was quoted as saying, "The European approval of JETREA just weeks after the US launch is another major milestone for the Company as we maintain, with our partner Alcon, the momentum of the global roll out of this novel pharmacological treatment for symptomatic VMA". He further added that the recent launch of Jetrea has turned the company into a fully integrated profitable company.
You may have head Adam Milstein's name before as a...Read More
In late March, a student from Bordeaux was enjoying...Read More
Paris and London, two of the most beautiful capital...Read More